AbbVie Inks $2.9 Billion Cancer Deal With China’s I-Mab
A research associate works at the Moderna Therapeutics Inc. lab in Cambridge, Massachusetts, U.S. (Photographer: Adam Glanzman/Bloomberg)

AbbVie Inks $2.9 Billion Cancer Deal With China’s I-Mab

(Bloomberg) -- U.S. drugmaker AbbVie Inc. and Chinese drug developer I-Mab agreed to collaborate on a cancer treatment in a deal that could be worth more than $2.9 billion.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.